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EDITORIAL
Studies  on  lung  cancer  management  in routine  practice ca
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In  the  present  issue  of  the  Portuguese  Journal  of  Pul-
monology  appears  a  hospital-based  study  about  lung  cancer
in  Northern  Portugal1 The  authors  have  registered  during  an
eleven  years  period  (2000  --  2010)  the  cases  of  lung  can-
cer  managed  in  a  network  of  hospitals  in  Northern  Portugal.
They  collected  information  about  9767  patients  with  a  sig-
niﬁcant  increase  in  the  number  of  cases  from  2000  (634
cases)  to  2010  (1284  cases).  Collected  data  include  demo-
graphic  characteristics,  smoking  habits,  performance  status,
histology,  stage,  treatment  strategy.  Survival,  speciﬁc  mor-
tality  and  causes  of  death  were  not  reported.  There  was  an
increase  of  adenocarcinoma  histological  type  as  well  as  more
lung  cancers  in  women.  The  authors  observed  also  over  time
a  signiﬁcant  increase  of  combined  therapeutic  modalities.
This  type  of  study  is  important  because  it  allows  deter-
mining  how  thoracic  oncology  is  practiced  in  speciﬁc  settings
or  countries  without  selection  of  the  patients  according  to
trials  criteria.  It  may  somehow  give  a  picture  how  guide-
lines  or  recent  studies  results  are  implemented  in  the  daily
practice.  In  the  present  report,  the  authors  consider  to  have
included  about  one  third  of  the  total  number  of  lung  cancer
diagnosed  in  their  catchment  area.  In  comparison,  registries
have  the  advantage  to  include  all  the  cases  of  the  area  with-
out  any  selection  but  information  about  individual  patients
is  often  limited.
Other  studies  performed  with  unselected  patients  pop-
ulation  are  implementation  studies  where  a  speciﬁc
treatment  or  approach  is  assessed  in  routine  practice.  This
very  important  information  is  often  lacking  in  the  literature,
particularly  concerning  guidelines.  We  have  conducted  a  few
implementation  studies  to  determine  if  the  results  that  are
obtained  with  a  given  treatment  in  routine  practice  are  con-
sistent  with  those  reported  by  the  clinical  trials.  We  assessed
in  advanced  non-small  cell  lung  cancer  by  such  an  approach
the  MIP  (mitomycin  +  ifosfamide  +  cisplatin)  regimen  as  ﬁrst-
line  chemotherapy2 and  docetaxel3 and  pemetrexed4 as
salvage  chemotherapy.  The  results  that  we  obtained  in
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ll  those  retrospective  studies  showed  similar  activities
han  those  reported  in  clinical  prospective  trials,  suggesting
heir  generalizability  for  routine  practice  if  medical  contra-
ndications  are  respected.
French  authors  have  used  a  similar  approach  based  on
nselected  cohorts  as  in  the  Northern  Portugal  study.  This
tudy,  called  KPB-CPHG,  has  been  prospectively  performed
n  general  hospitals.  Two  cohorts  have  been  follow  up,  one  in
000  and  the  other  one  in  2010  with  the  respective  participa-
ion  of  137  and  104  centres  that  have  included  5667  and  7051
atients5--8. They  observed  that  over  ten  years,  lung  can-
er  characteristics  have  changed  with  more  women,  more
ever-smokers,  and  more  adenocarcinomas.  That  observa-
ion  is  similar  to  the  presently  reported.  In  the  French  study,
urvival  was  also  registered  and  results  with  the  ﬁrst  cohort
ere  published,  showing  an  overall  10.4%  5-year  survival.
he  impact  of  treatment  strategy  has  also  been  assessed
ith  better  survival  when  patients  were  treated.
Registries  can  also  provide  interesting  information.
hey  have  the  advantage  to  deal  with  large  number  of
atients  but  the  number  of  collected  data  is  usually  limited,
recluding  in-depth  analysis.  The  SEER  (for  Surveillance,
pidemiology  and  End  Results)  registry  is  widely  used  for
urposes  as  the  study  of  lung  cancer  in  women9,  the  inﬂu-
nce  of  hospital  volume  on  survival  after  resection  for
ung  cancer10,  the  effect  of  race  on  invasive  staging  and
urgery  in  non-small-cell  lung  cancer11,  the  role  of  postop-
rative  radiotherapy12,  or  the  management  of  stage  III  and
V  NSCLC13.  Other  good  registries  are  also  available  in  the
nited  Kingdom,  Scandinavia  and  the  Netherlands,  allowing
erforming  similar  studies.
An  important  question  is  the  level  of  evidence  of  the
tudy  reported  in  the  present  issue  of  the  Portuguese  Jour-
al  of  Pulmonology.  Whatever  implementation,  cohort  or
egistries  studies,  all  deal  with  unselected  patients’  popu-
ation,  contrary  to  clinical  trials.  In  term  of  evidence-based
edicine,  randomised  clinical  trials  are  considered  as  the
14,15est  level  of  evidence ,  followed  by  prospective  studies
ith  a  control  group,  comparative  studies  with  historical
ontrols,  prospective  cohorts  without  control  group,  ret-
ospective  studies  and  case  reports.  If  this  is  true  from  a
gia.  Published  by  Elsevier  España,  S.L.  All  rights  reserved.
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cientiﬁc  point  of  view  (internal  validity)  because  randomi-
ation  minimises  the  risk  of  bias,  it  is  less  true  for  external
alidity.  Indeed,  the  patients  selected  for  trials  are  often
 small  part  of  the  whole  group  of  patients  which  we  have
o  treat.  Patients  which  are  compromised  by  conditions  such
s  poor  performance  status,  organ  failures,  other  severe  dis-
ases,  or  old  age,  are  often  excluded  for  trials  but  not  for
outine  treatment.  In  fact,  results  of  clinical  trials  should
e  conﬁrmed  by  studies  conducted  in  the  context  of  the
aily  practice  where  patients  do  not  receive  the  recom-
ended  therapy  only  in  case  of  medical  contra-indication
o  its  administration.  Those  studies  of  which  methodology
hould  be  better  deﬁned  are  the  best  level  evidence  for
eneralizability  (external  validation). A  similar  approach
hould  be  recommended  for  practice  guidelines.  Indeed,  a
ot  of  guidelines  are  today  published  but  none  have  been  so
ar  validated  by  implementation  studies.
Today,  the  performance  of  a  prospective  clinical  trial  has
ecome  very  complicated  and  expansive.  A lot  of  bureau-
ratic  rules  and  a  high  cost  have  led  to  a  considerable
eduction  of  the  number  of  academic  trials.  Most  of  the  ran-
omised  clinical  trials  testing  drugs  are  conducted  by  the
harmaceutical  industry  for  registration  purposes.  A  new
ole  for  academic  research  is  to  develop  external  validation
n  unselected  patients’  population,  allowing  generalisation
f  the  registered  treatment.  Otherwise,  the  drug  prescrip-
ion  should  be  restricted  to  the  criteria  and  conditions  with
hich  the  registration  studies  were  performed.
Today,  the  external  validation  studies  are  mainly  pub-
ished  in  the  national  medical  press  and  often  in  the  native
anguage.  Indeed,  an  important  parameter  that  has  to  be
onsidered  in  such  studies  is  the  inﬂuence  of  the  social  secu-
ity  system  (including  rules  for  reimbursement)  and  of  the
ocal  health  care  organisation.  This  is  a  barrier  for  publi-
ation  in  the  journal  with  good  impact  factors,  which  are
ighly  biased  in  favour  of  the  native  English-speaking  world.
aking  all  those  elements  in  consideration,  studies  like  that
resently  reported  can  have  major  care  impact,  particu-
arly  if  survival  is  taken  into  account  and  correlated  with
reatment  administered  over  time.  They  also  should  allow
alidation  of  guidelines  in  the  daily  practice.
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